TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04569227: Prevention of COVID-19 Infection to Severe Pneumonia or ARDS

Sponsor: Enzychem Lifesciences Corporation · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 60 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$4,674,600

Rescue Site Savings

+$3,087,000

Unlock Full NCT04569227 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04569227 Rescue Dossier →